5 Times Wins Teva's first biosimilar to Rituxima for the treatment of RA is launched in the U.S. Is gabapentin effective in treating neuropathic eye pain caused by dry eye? Hidden dragon in the abyss: ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Teva announced it was partnering with Sanofi to further develop duvakitug for treatment of IBD in October last year. The drug was developed by the Israeli big pharma to target TL1A (TNF superfamily ...

ADRs of Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) traded higher in the premarket on Tuesday after the companies said that their experimental antibody therapy, duvakitug, reached the ...

With the new findings in hand, Sanofi and Teva are now plotting a phase 3 study for duvakitug, pending talks with regulators. Duvakitug hails from Teva’s labs, though Sanofi got in on the action ...

Teva Pharmaceuticals' shares soared and Sanofi's stock moved higher following positive results from the latest trial of their jointly developed treatment for inflammatory bowel disease. The ...

JERUSALEM, Dec 17 (Reuters) - (This Dec.17 story has been corrected to say the results were for ulcerative colitis, not for both the diseases, in paragraph 5) Teva and Sanofi said last year they ...

Duvakitug isn't just another drug in Teva's pipelineit's the drug. With consistent efficacy across patient groups and no major safety hiccups, this TL1A antibody therapy is now a frontrunner in ...

A Teva Pharmaceuticals drug being developed in partnership with Sanofi to hit a promising but competitive target for inflammation now has positive data from a clinical test in the two most common ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Teva (TEVA) Pharmaceuticals announced the launch of a new patient access program, in partnership with Direct Relief, to supply inhalers to eligible patients in the United States free of charge ...

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced that it will divest Teva-Takeda, its business venture in Japan, to JKI Co., Ltd. The divestment, which includes generics and legacy ...